Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.

被引：0
|
作者：
Chang, Kevin [1 ]
Lodha, Roshan [2 ]
Delavan, Henry M. [3 ]
Winebaum, Jenna [3 ]
Porten, Sima P. [1 ]
Feng, Felix Y. [3 ]
Chu, Carissa E. [1 ]
Chou, Jonathan
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Cleveland Clin, Lerner Coll Med, Cleveland Hts, OH USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
3282-646-2719; 613-615-646-4685-2424; 283-183-138-226-9326; 283-183-138-11076; 261-374-2500-10670-7136; 5; 3; 2; 3224; 1876; 1; 38092-33344; 38092-27054;
D O I：
10.1200/JCO.2024.42.4_suppl.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：690 / 690
页数：1
相关论文
共 50 条
  • [41] Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
    Mimura, Yuji
    Kobayashi, Aya
    Utazu, Haruhiko
    Matsumoto, Yuki
    Mizusawa, Hiroya
    IJU CASE REPORTS, 2023, 6 (02) : 111 - 115
  • [42] Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study
    Nazha, Bassel
    Brown, Jacqueline T.
    Liu, Yuan
    Kissick, Haydn
    Carthon, Bradley Curtis
    Kucuk, Omer
    Harik, Lara R.
    Narayan, Vikram M.
    Joshi, Shreyas S.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Cellular resistance mechanisms in cancer and the new approaches to overcome resistance mechanisms chemotherapy
    Al Saihati, Hajir A.
    Rabaan, Ali A.
    SAUDI MEDICAL JOURNAL, 2023, 44 (04) : 329 - 344
  • [44] Mechanisms and Strategies to Overcome Resistance to Molecularly Targeted Therapy for Melanoma
    Lim, Su Yin
    Menzies, Alexander M.
    Rizos, Helen
    CANCER, 2017, 123 : 2118 - 2129
  • [45] Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer
    Uzzo, Robert G.
    Haas, Naomi B.
    Crispen, Paul L.
    Kolenko, Vladimir M.
    CANCER, 2008, 112 (08) : 1660 - 1671
  • [46] Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
    Luque-Cabal, Maria
    Garcia-Teijido, Paula
    Fernandez-Perez, Yolanda
    Sanchez-Lorenzo, Luisa
    Palacio-Vazquez, Isabel
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 21 - 30
  • [47] Determining fi tness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments
    Russell, B. M.
    Fein, D. E. C.
    Bellmunt, J.
    ESMO OPEN, 2024, 9 (11)
  • [48] Targeting MET and RON to overcome cetuximab resistance in colorectal cancer.
    Graves-Deal, Ramona
    Bogatcheva, Galina
    Damalanka, Vishnu
    Klampfer, Lidija
    Janetka, James W.
    Coffey, Robert J.
    Singh, Bhuminder
    CANCER RESEARCH, 2021, 81 (13)
  • [49] Manipulation of β-catenin pathway to overcome endocrine resistance in breast cancer.
    Won, Hye Sung
    Lee, Kyoung Eun
    Lee, Kyung Mee
    Nam, Eun Mi
    Mun, Yeung Chul
    Seong, Chu-Myong
    Lee, Soon-Nam
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Resistance mechanisms and therapeutic strategies to overcome the resistance in driver oncogene positive NSCLC
    Katayama, Ryohei
    Fujita, Naoya
    CANCER SCIENCE, 2018, 109 : 817 - 817
12345